CANVAS study presented at ADA 2017 highlights heart and kidney protection for type 2 diabetes drug Invokana, and questions persist over an increased risk of amputations
Research
The latest research in type 1 diabetes, type 2 diabetes, prediabetes, and beyond. Here you’ll find information on experimental therapies, new data and results, and scientific findings.
45 readers recommended
Research reveals improved A1c and weight loss benefits for people with type 1 diabetes on sotagliflozin, but a slightly increased risk of DKA
38 readers recommended
FDA Approves New GLP-1 Label on Victoza to show that the medicine makes hearts healthier!
50 readers recommended
A recent trial comparing once-weekly GLP-1 agonists semaglutide and Trulicity found improved A1c and double the weight loss with semaglutide
41 readers recommended
Trial results testing sotagliflozin and Farxiga in type 1 diabetes show greater A1c lowering and weight loss, plus continued conversation about small risk of DKA
35 readers recommended
Results from the type 2 diabetes group in Dexcom’s DIaMonD trial show A1c and time-in-range benefits
48 readers recommended
The latest evidence on Saxenda shows that three years of treatment with the drug lowers risk for type 2 diabetes by an impressive 79%
37 readers recommended
New CONCEPTT trial results show improved newborn health and more time-in-range in women with type 1 diabetes using CGM during pregnancy
23 readers recommended
Physicians, diabetes educators, and research scientists share their own health bright spots in food and exercise, technology, and more
30 readers recommended
An app uses blood sugar readings and other diabetes information to provide personalized guidance to workouts, along with exercise videos specifically for people with...
32 readers recommended
Ketogenic (low-carb + high-fat) diet and remote coaching to “reverse” type 2 diabetes shows 60% of participants had type 2 “reversed," 94% of insulin users reduced or...
32 readers recommended
Trial shows that a pill version of Ozempic (semaglutide) can lower A1c by as much as 1.5% and also support weight loss
34 readers recommended
Read about combo drug Xultophy, Toujeo vs. Tresiba, diabetes apps, the do-it-yourself community, FreeStyle Libre real-world data, and more!
41 readers recommended
The results were so positive it was deemed unethical to keep giving people placebo instead of Invokana, an SGLT-2 inhibitor approved for type 2 diabetes
34 readers recommended
A huge milestone that makes Forxiga the first pill for people with type 1 diabetes in Europe
37 readers recommended
Zealand Pharma shared positive trial results for its dasiglucagon – 99% of participants recovered from hypo within 15 minutes of treatment
42 readers recommended
Results from the CREDENCE trial suggest that Invokana’s kidney benefits exist on top of blood pressure lowering medications (standard of care)
36 readers recommended
Why it’s a big deal for the closed loop and pump fields, when it might be available, and how Tidepool is working with the FDA and companies to make it happen
41 readers recommended
The EMA approved Zynquista (sotagliflozin), an SGLT-1/2 dual inhibitor, for adults with a BMI above 27
33 readers recommended
Surprising study findings from a look at refrigerator temperatures and the risk posed to insulin quality; plus, a guide to safe insulin storage and Med Angel’s very cool...